CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Research Progress in Immunotherapy of Gliomas.
Research Progress in Immunotherapy of Gliomas.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
尽管肿瘤治疗取得了一些进展,但胶质瘤仍然是严重威胁人类生命健康的肿瘤之一。由于中枢神经系统免疫微环境的特殊性以及肿瘤的高侵袭性,胶质瘤的治疗仍然是一个重大挑战。目前,研究人员已经探索了大量免疫治疗方案以改善胶质瘤患者的生存和预后,包括肿瘤疫苗、免疫检查点抑制剂、过继性细胞转移疗法、病毒载体疗法和基因工程疗法。这些方案的目标是通过药物激活或改变免疫抑制环境并靶向肿瘤细胞,结合手术切除、放疗、化疗和抗血管生成药物,达到治疗胶质瘤的目的。本综述简要描述了胶质瘤的免疫抑制微环境,并总结了近期的免疫治疗策略及其进展。目的是总结治疗胶质瘤的最新免疫疗法并提供新的研究方向。
Although some progress has been made in tumor treatment, gliomas remain one of the tumors that can still seriously threaten human life and health. Due to the particularity of the immune microenvironment of the central nervous system and the strong invasiveness of tumors, the treatment of gliomas remains a major challenge. Currently, researchers have explored a large number of immunotherapy programs to improve the survival and prognosis of glioma patients, including tumor vaccines, immune checkpoint inhibitors, adoptive cell transfer therapy, viral vector therapy, and genetic engineering therapy.
The goal of these programs is to activate or change the immunosuppressive environment and target tumor cells through drugs, combined with surgical resection, radiotherapy, chemotherapy, and anti-angiogenesis drugs, to achieve the purpose of treating glioma. This review briefly describes the immunosuppressive microenvironment of gliomas and summarizes recent immunotherapeutic strategies and their progress. The aim is to summarize the latest immunotherapies for the treatment of gliomas and provide new research directions.
MEMBER ACCOUNT
登录成功会直接打开下一页。